Original Article| Volume 166, ISSUE 6, P650-659, December 2015

Changes of soluble CD40 ligand in the progression of acute myocardial infarction associate to endothelial nitric oxide synthase polymorphisms and vascular endothelial growth factor but not to platelet CD62P expression

      Reported in vitro data implicated soluble CD40 ligand (sCD40L) in endothelial dysfunction and angiogenesis. However, whether sCD40L could exert that influence in endothelial dysfunction and angiogenesis after injury in acute myocardial infarction (AMI) patients remains unclear. In the present study, we evaluated the association of sCD40L with markers of platelet activation, endothelial, and vascular function during a recovery period early after AMI. To achieve this goal, the time changes of soluble, platelet-bound, and microparticle-bound CD40L levels over 1 month were assessed in AMI patients and correlated with endothelial nitric oxide synthase (eNOS) polymorphisms, vascular endothelial growth factor (VEGF) concentrations, and platelet expression of P-selectin (CD62P). The association of soluble form, platelet-bound, and microparticle-bound CD40L with CD62P expression on platelets, a marker of platelet activation, was also assessed to evaluate the role of CD40L in the thrombosis, whereas the association with eNOS and VEGF was to evaluate the role of CD40L in vascular dysfunction. This work shows for the first time that time changes of sCD40L over 1 month after myocardial infarct onset were associated with G894T eNOS polymorphism and with the VEGF concentrations, but not to the platelet CD62P expression. These results indicate that, in terms of AMI pathophysiology, the sCD40L cannot be consider just as being involved in thrombosis and inflammation but also as having a relevant role in vascular and endothelial dysfunction.


      AMI (acute myocardial infarction), APC (allophycocyanin), Asp (aspartate), cTNT (cardiac troponin), CAD (coronary artery disease), CRP (C-reactive protein), CK (creatine kinase), eNOS (endothelial nitric oxide synthase), ELISA (enzyme-linked immunosorbent assay), FITC (fluorescein isothiocyanate), FAU (fluorescence arbitrary units), Glu (glutamic acid), LME (linear mixed effects model), MPs (microparticles), NO (nitric oxide), NT-proBNP (N-terminal pro-brain natriuretic peptide), PCI (percutaneous coronary intervention), PBS (phosphate-buffered saline), PE (Phycoerythrin), CD62P (P-selectin), sCD40L (soluble CD40 ligand), SA (stable angina pectoris), VEGF (vascular endothelial growth factor)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mach F.
        • Schönbeck U.
        • Sukhova G.K.
        • et al.
        Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis.
        Proc Natl Acad Sci U S A. 1997; 94: 1931-1936
        • Aukrust P.
        • Müller F.
        • Ueland T.
        • et al.
        Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes.
        Circulation. 1999; 100: 614-620
        • Muhammad R.
        • Pathak D.
        • Freedman J.E.
        • Chakrabarti S.
        CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease.
        Trends Mol Med. 2008; 14: 530-538
        • Santilli F.
        • Basili S.
        • Ferroni P.
        • Davì G.
        CD40/CD40L system and vascular disease.
        Intern Emerg Med. 2007; 2: 256-268
        • Lutgens E.
        • Lievens D.
        • Beckers L.
        • Donners M.
        • Daemen M.
        CD40 and its ligand in atherosclerosis.
        Trends Cardiovasc Med. 2007; 17: 118-123
        • Zhang B.
        • Wu T.
        • Chen M.
        • Zhou Y.
        • Yi D.
        • Guo R.
        The CD40/CD40L system: a new therapeutic target for disease.
        Immunol Lett. 2013; 153: 58-61
        • Varo N.
        • de Lemos J.A.
        • Libby P.
        • et al.
        Soluble CD40L: risk prediction after acute coronary syndromes.
        Circulation. 2003; 108: 1049-1052
        • Brueckmann M.
        • Bertsch T.
        • Lang S.
        • et al.
        Time course of systemic markers of inflammation in patients presenting with acute coronary syndromes.
        Clin Chem Lab Med. 2004; 42: 1132-1139
        • Kinlay S.
        • Schwartz G.
        • Olsson A.
        • et al.
        Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study.
        Circulation. 2004; 110: 386-391
        • Urbich C.
        • Dernbach E.
        • Aicher A.
        • Zeiher A.M.
        • Dimmeler S.
        CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species.
        Circulation. 2002; 106: 981-986
        • Furman M.I.
        • Krueger L.A.
        • Linden M.D.
        • Barnard M.R.
        • Frelinger III, A.L.
        • Michelson A.D.
        Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
        J Am Coll Cardiol. 2004; 43: 2319-2325
        • Chen C.
        • Chai H.
        • Wang X.
        • et al.
        Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells.
        Blood. 2008; 112: 3205-3216
        • Hristov M.
        • Gümbel D.
        • Lutgens E.
        • Zernecke A.
        • Weber C.
        Soluble CD40 ligand impairs the function of peripheral blood angiogenic outgrowth cells and increases neointimal formation after arterial injury.
        Circulation. 2010; 121: 315-324
        • Wolf D.
        • Hohmann J.-D.
        • Wiedemann A.
        • et al.
        Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis—but does not affect immunity and thrombosis in mice.
        Circ Res. 2011; 109: 1269-1279
        • Luo J.-Q.
        • Wen J.-G.
        • Zhou H.-H.
        • Chen X.-P.
        • Zhang W.
        Endothelial nitric oxide synthase gene G894T polymorphism and myocardial Infarction: a meta-analysis of 34 studies involving 21068 subjects.
        PLoS One. 2014; 9: e87196
        • Çiftçi Ç.
        • Melil S.
        • Çebi Y.
        • et al.
        Association of endothelial nitric oxide synthase promoter region (T-786C) gene polymorphism with acute coronary syndrome and coronary heart disease.
        Lipids Health Dis. 2008; 7: 5
        • Armstrong E.J.
        • Morrow David A.
        • Sabatine Marc S.
        Inflammatory biomarkers in acute coronary syndromes. Part III: biomarkers of oxidative stress and angiogenic growth factors.
        Circulation. 2006; 113: e289-e292
        • Di Marco G.S.
        • Reuter Stefan
        • Hillebrand Uta
        • et al.
        The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD.
        J Am Soc Nephrol. 2009; 20: 2235-2245
        • Petrovic D.
        The role of vascular endothelial growth factor gene as the genetic marker of atherothrombotic disorders and in the gene therapy of coronary artery disease.
        Cardiovasc Hematol Agents Med Chem. 2010; 8: 47-54
        • Ramos C.
        • Napoleão P.
        • Selas M.
        • et al.
        Prognostic value of VEGF in patients submitted to percutaneous coronary intervention.
        Dis Markers. 2014; 201: 135357
        • Chung I.
        • Choudhury A.
        • Patel J.
        • Lip G.Y.H.
        Soluble CD40L, platelet surface CD40L and total platelet CD40L in congestive heart failure: relationship to platelet volume, mass and granularity.
        J Intern Med. 2008; 263: 313-321
        • Napoleão P.
        • Santos M.C.
        • Selas M.
        • Viegas-Crespo A.M.
        • Pinheiro T.
        • Cruz Ferreira R.
        Variations in inflammatory markers in acute myocardial infarction: a longitudinal study.
        Rev Port Cardiol. 2007; 26: 1357-1363
        • Napoleão P.
        • Selas M.
        • Freixo C.
        • et al.
        The role of inflammatory biomarkers in the assessment of coronary artery disease.
        in: Baskot B. Coronary angiography—advances in noninvasive imaging approach for evaluation of coronary artery disease. InTech, Rijeka, 2011
        • Dominguez-Rodriguez A.
        • Abreu-Gonzalez P.
        • Garcia-Gonzalez M.J.
        • Kaski J.C.
        Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation.
        Thromb Res. 2009; 123: 617-621
        • Ahn E.R.
        • Lander G.
        • Jy W.
        • et al.
        Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk.
        Thromb Res. 2004; 114: 143-148
        • Varo N.
        • Nuzzo R.
        • Natal C.
        • Libby P.
        • Schönbeck U.
        Influence of pre-analytical and analytical factors on soluble CD40L measurements.
        Clin Sci. 2006; 111: 341-347
        • Monteiro M.C.
        • Sansonetty F.
        • Gonçalces M.J.
        • O'Connor J.E.
        Flow cytometric kinetic assay of calcium mobilization in whole blood platelets using Fluo-3 and CD41.
        Cytometry. 1999; 35: 302-310
        • Bernal-Mizrachi L.
        • Jy W.
        • Fierro C.
        • et al.
        Endothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromes.
        Int J Cardiol. 2004; 97: 439-446
        • Nieuwland R.
        • Berckmans R.J.
        • Rotteveel-Eijkman R.C.
        • et al.
        Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant.
        Circulation. 1997; 96: 3534-3541
        • Dignat-George F.
        • Sabatier F.
        • Camoin-Jau L.
        • Sampol J.
        Measuring circulating cell-derived microparticles.
        J Thromb Haemost. 2004; 2: 1844-1845
        • Shet A.S.
        • Key N.S.
        • Hebbel R.P.
        Measuring circulating cell-derived microparticles.
        J Thromb Haemost. 2004; 2: 1848-1850
        • Colombo M.G.
        • Paradossi U.
        • Andreassi M.G.
        • et al.
        Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease.
        Clin Chem. 2003; 49: 389-395
        • Henn V.
        • Steinbach S.
        • Büchner K.
        • Presek P.
        • Kroczek R.A.
        The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40.
        Blood. 2001; 98: 1047-1054
        • Weber A.-A.
        • Hermann A.
        • Rauch B.H.
        • Schrör K.
        Molecular identity of platelet CD40L ligand (CD40L).
        Thromb Haemost. 2001; 86: 718
        • da Costa Escobar Piccoli J.
        • Manfredini V.
        • Hamester F.I.
        • et al.
        Interaction between endothelial nitric oxide synthase gene polymorphisms (–786T>C, 894G>T and intron 4 a/b) and cardiovascular risk factors in acute coronary syndromes.
        Arch Med Res. 2012; 43: 205-211
        • Tesauro M.
        • Thompson W.C.
        • Rogliani P.
        • Qi L.
        • Chaudhary P.P.
        • Moss J.
        Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298.
        Proc Natl Acad Sci U S A. 2000; 97: 2832-2835
        • Hingorani A.D.
        • Liang C.F.
        • Fatibene J.
        • et al.
        A common variant of the endothelial nitric oxide synthase (Glu298/Asp) is a major risk factor for coronary artery disease in the UK.
        Circulation. 1999; 100: 1515-1520
        • Hojo Y.
        • Ikeda U.
        • Zhu Y.
        • et al.
        Expression of vascular endothelial growth factor in patients with acute myocardial infarction.
        J Am Coll Cardiol. 2000; 35: 968-973
        • Petrovic D.
        • Verhovec R.
        • Globocnik Petrovic M.
        • Osredkar J.
        • Peterlin B.
        Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes.
        Cardiology. 2007; 107: 291-295
        • Lim H.S.
        • Tayebjee M.H.
        • Tan K.T.
        • Patel J.V.
        • MacFadyen R.J.
        • Lip G.Y.H.
        Is soluble CD40 ligand a mediator of angiogenesis in patients with coronary artery disease?.
        Thromb Res. 2008; 122: 307-313
        • Melter M.
        • Reinders M.E.J.
        • Sho M.
        • et al.
        Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo.
        Blood. 2000; 96: 3801-3808
        • Blann A.D.
        • Choudhury A.
        • Freestone J.
        • Patel J.
        • Lip G.Y.H.
        Soluble CD40 ligand and atrial fibrillation: relationship to platelet activation, and endothelial damage/dysfunction.
        Int J Cardiol. 2008; 127: 135-137
        • Semb A.G.
        • van Wissen S.
        • Ueland T.
        • et al.
        Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.
        J Am Coll Cardiol. 2003; 41: 275-279
        • Alber H.F.
        • Frick M.
        • Suessenbacher A.
        • et al.
        Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease–a randomized, placebo-controlled study.
        Am Heart J. 2006; 151: 139
        • Santini E.
        • Madec S.
        • Corretti V.
        • Ferrannini E.
        • Solini A.
        Effect of statins on soluble CD40 ligand in hypercholesterolemic type 2 diabetic patients.
        J Endocrinol Invest. 2008; 31: 660-665
        • Park M.W.
        • Her S.H.
        • Cho J.S.
        • et al.
        Triple antiplatelet therapy (aspirin, clopidogrel, cilostazol) loading followed by maintenance reduces greater serum level of sCD40L and TNF-a than dual antiplatelet therapy in patients with acute myocardial infarction undergoing PCI: two-center, prospective, open label, randomized, pilot study.
        Circulation. 2013; 128: A16074
        • Heeschen C.
        • Dimmeler S.
        • Hamm C.W.
        • et al.
        Soluble CD40 ligand in acute coronary syndromes.
        N Engl J Med. 2003; 348: 1104-1111
        • Yan J.C.
        • Zhu J.
        • Gao L.
        • et al.
        The effect of elevated serum soluble CD40 ligand on the prognostic value in patients with acute coronary syndromes.
        Clin Chim Acta. 2004; 343: 155-159
        • Schönbeck U.
        • Varo N.
        • Libby P.
        • Buring J.
        • Ridker P.M.
        Soluble CD40L and cardiovascular risk in women.
        Circulation. 2001; 104: 2266-2268
        • Youssef A.A.
        • Chang L.T.
        • Sheu J.J.
        • et al.
        Association between circulating level of CD40 ligand and angiographic morphologic features indicating high-burden thrombus formation in patients with acute myocardial infarction undergoing primary coronary intervention.
        Circ J. 2007; 71: 1857-1861